Uppmuntrande resultatförbättring under Q1. Framåt kvarstår en del orosmoln men Malmbergs framstår so...
Q1'23 due on Thursday, 4 May We lower '23e-'25e EBIT by 10-16% The share is trading at 14x P/E on 20...
Redeye expected significantly stronger Q1 numbers from OXE Marine.
We lower '23e-'25e EBITA by 9-7% Utilisation down to normal levels B3 Poland margin accretive Takea...
Bonesupports första kvartal kom in över våra förväntningar och tillväxtutsikterna ser starka ut.
Mangold uppdaterar investmentbolaget Capsek, som expanderat till norra Sverige, med lokalförankring ...
CapMan’s Q1 results were quite weak on paper, but the operational performance remained at a rather g...
Exel’s Q1 results came in clearly below our and consensus estimates.
Q1 profitability came in soft. While growth is expected going forward, the extent of profitability r...
Denmark slows while UK continues its strong trend Adj.
Redeye returns with a more detailed take on Episurf Medicals’ Q1 report, and we make some changes to...
Redeye comments on Zordix ahead of its Q1-results (due 17 May) where we expect the company to see st...
Redeye updates its estimates and valuation on the back of the Q1 2023 report, where ARR and recurrin...
Redeye thinks that Sensys Gatso currently displays extraordinarily low sales and an extraordinarily ...
Rovio's Q1 was merely a formality after the recent recommended cash offer of EUR 9.
CapMan's Q1 EBIT came in well below Refinitiv consensus expectations due to fair value changes, driv...
36% org growth, 21% adj. EBIT beat on strong AM sales 27% adj.
We lower '23e-'25e sales by 8-10% Algo to rebound no earlier than H2'23e Rights issue implies '23e E...
Q1 report due on Thursday, 4 May We lower '23e sales by ~4% as we trim Circular Energy sales The sha...
Orders remain strong while EBIT turns positive 4.2-9.
